ScienceLife Sciences

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Play

Open in

86 episodes
Avg 6 min
English

Episodes 86

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

Yesterday · 2 min
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.
Thursday · 2 min
Pharmaceutical Executive Daily: Egetis Sells Priority Review Voucher for $190 Million
ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, and Ignite Proteomics’ Dr. Brian Corgiat on improving how tumors are tested after recurrence.
Wednesday · 2 min
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
Monday · 2 min
Pharmaceutical Executive Daily: FDA Approves Voceryq
FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.
Monday · 32 min
States Take Center Stage in the Drug Pricing Fight
In this episode of the Pharmaceutical Executive podcast, Scott LaGanga, executive vice president of state advocacy at PhRMA, discusses the expanding influence of state policymaking on drug pricing, pharmacy benefit manager reform, and efforts to translate policy changes into lower out-of-pocket costs for patients. Joining Mike Christel, group managing editor, MJH Life Sciences, LaGanga also dives into the potential impact of tomorrow's U.S. midterm elections in shaping the next wave of drug pricing policy in state capitals as much as in Washington. Noting the high stakes, LaGanga explains why turnover in governors’ offices and state legislatures puts fresh urgency on educating policymakers about the pharmaceutical supply chain — and how decisions in states can move quickly and spread across the country. He also considers how the presidential campaign cycle that follows could bring local health care access and affordability concerns further into the national debate.
October 26 · 2 min
Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb
Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.
October 26 · 37 min
The Ron Lanton Report: A Conversation with Dr. Nadine Zawadzki
Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.
October 23 · 2 min
Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.
October 23 · 37 min
Building Biopharma Manufacturing for Speed, Scale, and Flexibility
Biopharma manufacturing today is being asked to move faster, accommodate increasingly complex modalities, and respond more readily to changing development timelines and demand forecasts — all while maintaining reliable, compliant, and cost-effective supply. In this episode of the Pharm Exec Podcast, Dave Maraldo, Ph.D., executive vice president and president of the Merck Manufacturing Division, draws on 27 years at the company to explore that evolution. He discusses Merck’s major U.S. capacity investments; its approach to balancing internal capabilities with strategic manufacturing partners; and the closer integration of research, development, and production. Joining Mike Christel, group managing editor, MJH Life Sciences, Maraldo also examines the practical impact of digital tools and artificial intelligence and how Merck is building greater agility and resilience into its global supply network. He reflects ahead as well on what the next generation of manufacturing talent will require and why he thinks patient needs will move closer and closer to the shop floor.
October 22 · 2 min
Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
October 21 · 2 min
Pharmaceutical Executive Daily: FDA Approves Hibsago
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
October 20 · 2 min
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli
METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.
October 19 · 2 min
Pharmaceutical Executive Daily: Hansoh Pharma Enters Collaboration and License Agreement with Roche for Broad Portfolio of ADCs
Merck KGaA, Darmstadt, Germany, acquires Silence Therapeutics for $1.3 billion, Hansoh Pharma and Roche expand their ADC partnership in a deal worth over $15 billion, and an EMA panel backs Lilly’s Foundayo for obesity and type 2 diabetes in Europe.
October 14 · 2 min
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
Gilead and Vir Biotechnology strike a $1.87 billion T-cell engager collaboration, and Fox Rothschild’s Marc Wagner examines what slows manufacturers’ response to rising drug demand and how compounding pharmacies help fill the resulting gaps.
October 13 · 2 min
Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Therapy with Roche
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona Therapeutics’ obesity RNAi candidate while Pfizer partners with Enodia Therapeutics on Sec61 inhibitors, and PaxSafe’s Mark Talens makes the case for acting on imperfect supply chain data.
October 12 · 2 min
Pharmaceutical Executive Daily: Thomas Appio Named Interim CEO of Bausch + Lomb
Bausch + Lomb names Thomas Appio interim CEO as Brent Saunders departs, a Pharm Exec interview explores how AI is reshaping entry-level apprenticeship in professional services, and a LogiPharma 2026 conversation makes the case against waiting for perfect data to deploy AI in pharma supply chains.
October 9 · 2 min
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
October 8 · 2 min
Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
October 7 · 2 min
Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.
October 6 · 3 min
Pharmaceutical Executive Daily: What HCP Engagement Actually Looks Like
Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.

Showing 1–20 of 86 episodes